pertuzumab trastuzumab Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

SOLTI Breast Cancer Research Group (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadbilateral breast cancer

I am/have/hadbreast cancer

I am/have/hadpik3ca

I am/have/hadneutrophil count

I am/have/hadHER2

I am/have/hadglomerular filtration rate

I am/have/hadher2/neu-positive breast cancer

I am/have/hadadjuvant therapy

I am/have/hadaptt

I am/have/hadbone metastases

I am/have/hadformalin-fixed paraffin-embedded

I am/have/hadher2 positive breast carcinoma

I am/have/hadejection fraction

I am/have/hadprogressive disease

I am/have/hadstage iv breast cancer

I am/have/hadmetastasis

I am/have/hadmetastatic adenocarcinoma

I am/have/hadplatelet count

I am/have/hadffpe

I am/have/hadhcg pregnancy test

added new label for I am/have/had

more

I am looking for

I am looking foripatasertib

I am looking forglycosylated hemoglobin

I am looking foradjuvant

I am looking fortaxane

I am looking forimmunological adjuvant

I am looking forpertuzumab

I am looking forpik3ca

I am looking fortrastuzumab

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

This is an open label, single arm, multicenter, phase Ib study to evaluate the safety and clinical activity of the combination of ipatasertib, trastuzumab and pertuzumab in patients with unresectable locally advanced or metastatic HER2-positive breast cancer with tumors harboring PIK3CA mutations, candidates to receive maintenance HP after first line …

glycosylated hemoglobin

bilateral breast cancer

breast cancer

pertuzumab

pik3ca

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.